Sarepta Therapeutics Shares Fall on Full-Year Outlook Cut, Swing to 1Q Loss

Dow Jones

May 07, 2025

By Connor Hart

Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market.

The stock tumbled 21%, to $36.75, in after-hours trading. Through Tuesday's close, shares have lost about two-thirds of their value in the past year.

The company after the bell said it now expects total net product revenues of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The new outlook additionally reflects updated projections for Elevidys, Sarepta's gene-therapy treatment for Duchenne muscular dystrophy.

The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses tied to a recent global licensing and collaboration agreement with Arrowhead Pharmaceuticals.

The company logged a loss of $447.5 million, or $4.60 a share, compared with a profit of $36.1 million, or 37 cents a share, a year earlier. Analysts surveyed by FactSet expected a loss of $3.21 a share.

On an adjusted basis, Sarepta notched a loss of $3.42 a share, compared with analyst views for adjusted earnings of $2.52.

Total revenue jumped 80%, to $744.9 million, topping the $687.5 million that analysts projected.

Research and development expenses were $773.4 million in the recent quarter, up from $200.4 million a year earlier.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

May 06, 2025 18:39 ET (22:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533699326"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533699326\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533699326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 06:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533699326","market":"hk","top_or_hot":-1,"title":"Sarepta Therapeutics Shares Fall on Full-Year Outlook Cut, Swing to 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. \n</p>\n<p>\n  The stock tumbled 21%, to $36.75, in after-hours trading. Through Tuesday's close, shares have lost about two-thirds of their value in the past year. \n</p>\n<p>\n  The company after the bell said it now expects total net product revenues of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The new outlook additionally reflects updated projections for Elevidys, Sarepta's gene-therapy treatment for Duchenne muscular dystrophy. \n</p>\n<p>\n  The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses tied to a recent global licensing and collaboration agreement with Arrowhead Pharmaceuticals. \n</p>\n<p>\n  The company logged a loss of $447.5 million, or $4.60 a share, compared with a profit of $36.1 million, or 37 cents a share, a year earlier. Analysts surveyed by FactSet expected a loss of $3.21 a share. \n</p>\n<p>\n  On an adjusted basis, Sarepta notched a loss of $3.42 a share, compared with analyst views for adjusted earnings of $2.52. \n</p>\n<p>\n  Total revenue jumped 80%, to $744.9 million, topping the $687.5 million that analysts projected. \n</p>\n<p>\n  Research and development expenses were $773.4 million in the recent quarter, up from $200.4 million a year earlier. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 18:39 ET (22:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Therapeutics Shares Fall on Full-Year Outlook Cut, Swing to 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Therapeutics Shares Fall on Full-Year Outlook Cut, Swing to 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 06:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. \n</p>\n<p>\n  The stock tumbled 21%, to $36.75, in after-hours trading. Through Tuesday's close, shares have lost about two-thirds of their value in the past year. \n</p>\n<p>\n  The company after the bell said it now expects total net product revenues of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The new outlook additionally reflects updated projections for Elevidys, Sarepta's gene-therapy treatment for Duchenne muscular dystrophy. \n</p>\n<p>\n  The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses tied to a recent global licensing and collaboration agreement with Arrowhead Pharmaceuticals. \n</p>\n<p>\n  The company logged a loss of $447.5 million, or $4.60 a share, compared with a profit of $36.1 million, or 37 cents a share, a year earlier. Analysts surveyed by FactSet expected a loss of $3.21 a share. \n</p>\n<p>\n  On an adjusted basis, Sarepta notched a loss of $3.42 a share, compared with analyst views for adjusted earnings of $2.52. \n</p>\n<p>\n  Total revenue jumped 80%, to $744.9 million, topping the $687.5 million that analysts projected. \n</p>\n<p>\n  Research and development expenses were $773.4 million in the recent quarter, up from $200.4 million a year earlier. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 18:39 ET (22:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533699326","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533699326","pubTimestamp":1746571140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market.The stock tumbled 21%, to $36.75, in after-hours trading. Through Tuesday's close, shares have lost about two-thirds of their value in the past year.The company after the bell said it now expects total net product revenues of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The new outlook additionally reflects updated projections for Elevidys, Sarepta's gene-therapy treatment for Duchenne muscular dystrophy.The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses tied to a recent global licensing and collaboration agreement with Arrowhead Pharmaceuticals.The company logged a loss of $447.5 million, or $4.60 a share, compared with a profit of $36.1 million, or 37 cents a share, a year earlier. Analysts surveyed by FactSet expected a loss","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Sarepta Therapeutics股价因全年前景下调而下跌，第一季度亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. \n\n\n  The stock tumbled 21%, to $36.75, in after-hours trading. Through Tuesday's close, shares have lost about two-thirds of their value in the past year. \n\n\n  The company after the bell said it now expects total net product revenues of $2.3 billion to $2.6 billion for the year, down from a prior forecast of $2.9 billion to $3.1 billion. The new outlook additionally reflects updated projections for Elevidys, Sarepta's gene-therapy treatment for Duchenne muscular dystrophy. \n\n\n  The cut came as Sarepta swung to a loss in the first quarter, hurt by higher research and development expenses tied to a recent global licensing and collaboration agreement with Arrowhead Pharmaceuticals. \n\n\n  The company logged a loss of $447.5 million, or $4.60 a share, compared with a profit of $36.1 million, or 37 cents a share, a year earlier. Analysts surveyed by FactSet expected a loss of $3.21 a share. \n\n\n  On an adjusted basis, Sarepta notched a loss of $3.42 a share, compared with analyst views for adjusted earnings of $2.52. \n\n\n  Total revenue jumped 80%, to $744.9 million, topping the $687.5 million that analysts projected. \n\n\n  Research and development expenses were $773.4 million in the recent quarter, up from $200.4 million a year earlier. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2025 18:39 ET (22:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}